ABSTRACT
Fecal microbiota transplantation (FMT) is a therapy that involves the transplantation of healthy human fecal microorganisms into the gut of patients to rebuild or consolidate the intestinal microecology. It has been utilized in many diseases. However, FMT had a limited effect on patients with small intestinal diseases because of the unique ecological characteristics of the microorganisms. Thus, we proposed a new microecology transplantation therapy called human intestinal fluid transplantation (HIFT). Human intestinal fluid can be collected through a nasojejunal tube and be made into capsules using the freeze-dried powder method. In addition, strict standards for donor screening and management have been established. We are currently developing a high-standard HIFT preparation system and conducting high-quality clinical studies to validate the safety and efficacy of HIFT combined with FMT.
ABSTRACT
Objective To explore the curative effect of minimally invasive percutaneous nephrolithotomy in treatment of recurrence of kidney stones after open operation.Methods 56 patients with postoperative recurrence of renalcalculi were retrospectively reviewed.They were randomly divided into the control group and the observation group.The observation group was treated by minimally invasive percutaneous nephrolithotomy,while the control group received the open operation.The stone clearance rate,operation time and hospitalization time of the two groups were compared.Results The stone clearance rate in the observation group was 92.86％,which was significantly higher than 64.29％ of the control group (x2 =11.37,P ＜ 0.05) ; The average operation time in the control group was (131.8 ± 8.9)min,which was more than (92.5 ± 5.4)min of the observation group ;The average hospital stay in the control group was (19.7 ± 3.2) days,which was more than (10.4 ± 2.6)days of the observation group,the differences were statistically significant (t =16.38,17.25,all P ＜0.05).Conclusion Minimally invasive percutaneous nephrolithotomy can improve the stone clearance rate in treatment of recurrent renal calculi after open operation,which can shorten the operation time and hospital stay,it is worth the clinical promotion.
ABSTRACT
Objective To evaluate the clinical efficiency of humanized anti-CD52 monoclonal antibody (Campath-1H) and anti-CD25 monoclonal antibody (Zenapax) induction therapy in intestinal transplantation patients.Method The data of 6 patients receiving Campath-1H and 5 patients receving Zenapax induction therapy in intestinal transplantation between 2007 and 2012 were analyzed retrospectively.The counts of peripheral blood lymphocytes and monocytes,incidence of rejection and infention,and liver and kidney toxicity of recipients were recorded before and 3 months after transplantation.Results Of 6 intestinal transplantation patients receiving Campath-1H induction therapy,1 died of acute heart failure on the postoperative day 3,and the rest 5 patients had a powerful depletion of lymphocytes and monocytes in 8 weeks,followed by gradual increases after 8 weeks.The percentage of peripheral blood CD3 + T cells,CD4 + T cells,and CD8 + T cells was dropped to 5％ before administration,and remained at a steady low level in the first 8 weeks after induction.Of 5 patients receiving Zenapax induction therapy,1 died of Aspergillus infection on the postoperative day 25,and the rest 4 patients had an obeivous increase of lymphocytes and monocytes on the postoperative day 1.Counts of lymphocytes and monocytes kept steady at normal levels from the 1st to 12th week.One case of mild rejection was found in Campath-1H group.One case of mild,one moderate and one severe rejection were detected in Zenapax group.All rejections were successfully cured by prompt anti-rejection therapy.There were no significant difference in serum creatimine,urea nitrogen,alanine aminotransferase or total bilirubin after 3 months in comparison to preoperation.Conclusion Both Campath-1H induction therapy and Zenapax induction therapy successfully induce immune tolerance in patients with intestinal transplantation.Campath-1H seems to offer better immunosuppression against Zenapax during the first 3 months posttransplantation.
